First-Line Treatment with Olaparib for Early Stage BRCA-Positive Ovarian Cancer: May It Be Possible? Hypothesis Potentially Generating a Line of Research

Federica Tomao; Serena Maria Boccia; Carolina Maria Sassu; Martina Chirra; Innocenza Palaia; Maria Cristina Petrella; Violante Di Donato; Nicoletta Colombo; Pierluigi Benedetti Panici

doi:10.2147/CMAR.S194874

First-Line Treatment with Olaparib for Early Stage BRCA-Positive Ovarian Cancer: May It Be Possible? Hypothesis Potentially Generating a Line of Research

Cancer Manag Res. 2020 Jul 7:12:5479-5489. doi: 10.2147/CMAR.S194874. eCollection 2020.

Authors

Federica Tomao¹, Serena Maria Boccia², Carolina Maria Sassu², Martina Chirra³, Innocenza Palaia², Maria Cristina Petrella⁴, Violante Di Donato², Nicoletta Colombo^{1

5}, Pierluigi Benedetti Panici²

Affiliations

¹ Department of Gynecologic Oncology, European Institute of Oncology (IEO) IRCCS, Milan, Italy.
² Department of Maternal and Child Health and Urological Sciences, "Sapienza" University of Rome,Polyclinic Umberto I, Rome, Italy.
³ Medical Oncology Unit, Department of Medicine, Surgery and Neurosciences, University of Siena, Siena, Italy.
⁴ Medical Oncology, AOUC University Hospital Careggi, Florence, Italy.
⁵ Department of Medicine and Surgery, University of Milan-Bicocca, Milan, Italy.

Abstract

Olaparib is currently approved in maintenance treatment of advanced ovarian cancer after response to first-line chemotherapy for breast related cancer antigens (BRCA) mutated patients. The use of this agent is based on data from SOLO1 study that observed a decreased risk of disease progression or death and a median progression-free survival about 36 months longer in case of therapy with olaparib. However, this trial recruited only patients with advanced stage ovarian cancer. The aim of this review is to retrace the available data in order to clarify the potential efficacy and feasibility of olaparib administration in newly diagnosed epithelial ovarian cancer also in early stages.

Keywords: BRCA mutation; PARPinhibitors; early stage ovarian cancer; newly diagnosed ovarian cancer; olaparib.

Publication types

Review